Bio-similar drug development and accessible drugs in the market for the treatment of Alzheimer's Disease: Current status

Abstract

A decade has passed since no new Alzheimer's disease (AD) therapies were approved, even though it is the leading motive of dementia in the modern era. The community of patients with AD leads to expansion. Anxiety, anger, and inappropriate behavior, as well as sleep difficulty and psychosis are frequent symptoms of Alzheimer's disease, which is characterized by cognitive decline but also by mood and behavioral symptoms. This study aims to assemble all probable bio-similar drugs of Alzheimer's disease that predict to help slow down the disease's development. In this study, we try to express the genetic factors, environmental factors and treatment associated bio-molecular drugs. Research articles, news stories, academic papers published in journals and government websites such as PubMed were used to conduct a comprehensive literature analysis on the development and availability of bio-similar drugs to treat AD. Alzheimer's disease affects an older population, making treatment more difficult. There is currently no medicine that can prevent or cure the condition. In order to improve public health, even a slight delay in the start ofsymptoms might have a significant influence. Studying prospective treatments for Alzheimer's disease as the illness's incidence rises is an ongoing process for researchers.